BLUE - bluebird bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
146.64
-9.54 (-6.11%)
At close: 4:00PM EDT

146.64 0.00 (0.00%)
After hours: 4:43PM EDT

Stock chart is not supported by your current browser
Previous Close156.18
Open155.27
Bid137.01 x 1800
Ask149.15 x 800
Day's Range146.13 - 156.93
52 Week Range87.49 - 199.70
Volume512,354
Avg. Volume548,168
Market Cap8.058B
Beta (3Y Monthly)2.78
PE Ratio (TTM)N/A
EPS (TTM)-10.68
Earnings DateApr 30, 2019 - May 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est175.89
Trade prices are not sourced from all markets
  • Business Wire10 hours ago

    bluebird bio Opens State-of-the-Art Gene and Cell Therapy Manufacturing Facility in Durham, North Carolina

    bluebird bio, Inc. (BLUE) today announced the official opening of its first wholly owned manufacturing facility in Durham, N.C., that will produce lentiviral vector for the company’s investigational gene and cell therapies, including: bb2121 and bb21217 for the treatment of multiple myeloma and potentially LentiGlobin™ for the treatment of transfusion-dependent β-thalassemia (TDT) and sickle cell disease. Gov. Roy Cooper, Secretary of Commerce Tony Copeland and local patient advocates will join chief bluebird Nick Leschly in a ribbon cutting ceremony at the 125,000-square-foot facility.

  • Markit10 days ago

    See what the IHS Markit Score report has to say about bluebird bio Inc.

    bluebird bio Inc NASDAQ/NGS:BLUEView full report here! Summary * Bearish sentiment is high Bearish sentimentShort interest | NegativeShort interest is high for BLUE with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting BLUE. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold BLUE had net inflows of $1.45 billion over the last one-month. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Celgene (CELG) Submits Application for MS Drug in Europe
    Zacks10 days ago

    Celgene (CELG) Submits Application for MS Drug in Europe

    Celgene (CELG) submits application for MS drug, ozanimod to the European Medicines Agency.

  • Here's Why bluebird bio Gained 16.3% in February
    Motley Fool12 days ago

    Here's Why bluebird bio Gained 16.3% in February

    The biopharma announced fourth-quarter 2018 operating results and reminded investors of its deep late-state pipeline.

  • Business Wire14 days ago

    bluebird bio to Present at Investor Conferences in March

    To access the live webcasts of bluebird bio’s presentations, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully.

  • What Are Analysts Saying About bluebird bio, Inc.’s (NASDAQ:BLUE) Earnings Outlook?
    Simply Wall St.15 days ago

    What Are Analysts Saying About bluebird bio, Inc.’s (NASDAQ:BLUE) Earnings Outlook?

    bluebird bio, Inc.'s (NASDAQ:BLUE) most recent earnings update in December 2018 signalled that losses became smaller relative to the prior year's level - great news for investors Below is aRead More...

  • With a Stocked War Chest, bluebird bio Presses On
    Motley Fool24 days ago

    With a Stocked War Chest, bluebird bio Presses On

    The biotech is on the verge of its first approval, with three more in the works.

  • Biotech ETFs Jump on Roche-Spark Deal
    Zacks24 days ago

    Biotech ETFs Jump on Roche-Spark Deal

    The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.

  • Better Buy: bluebird bio vs. Gilead Sciences
    Motley Fool27 days ago

    Better Buy: bluebird bio vs. Gilead Sciences

    Which stock wins in a battle between this up-and-coming biotech and a giant that dominates the HIV market?

  • bluebird (BLUE) Q4 Earnings Beat Estimates, Revenues Up Y/Y
    Zacks28 days ago

    bluebird (BLUE) Q4 Earnings Beat Estimates, Revenues Up Y/Y

    bluebird (BLUE) reports narrower-than-expected Q4 loss. The pipeline progress looks encouraging.

  • Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates
    Zacks29 days ago

    Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates

    Bluebird (BLUE) delivered earnings and revenue surprises of 3.89% and 96.00%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press29 days ago

    Bluebird: 4Q Earnings Snapshot

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $2.72. The results beat Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment ...

  • Business Wire29 days ago

    bluebird bio Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress

    - Strong 2018 marked by the company’s first European Marketing Authorization Application for LentiGlobin in transfusion-dependent β-thalassemia –

  • GlobeNewswirelast month

    Report: Exploring Fundamental Drivers Behind Tyson Foods, ElectraMeccanica Vehicles, Cousins Properties, Spirit Aerosystems, bluebird bio, and Yext — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Feb. 14, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline
    Zackslast month

    Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline

    Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma
    Zackslast month

    AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma

    AbbVie (ABBV) enters a global strategic transaction agreement with privately-held Teneobio to develop and commercialize the latter's pre-clinical immunotherapy candidate, TNB-383B, as a multiple myeloma treatment.

  • Business Wirelast month

    bluebird bio Appoints Chip Baird as Chief Financial Officer

    Mr. Baird joins bluebird from Amicus Therapeutics, Inc., where he was the CFO for the past seven years and brings a demonstrated track record of successfully leading companies in all phases of discovery, development and commercialization. Jeff Walsh, who has held various roles over the last eight years at bluebird bio — including chief operating officer and, most recently, chief financial and strategy officer — will assume the new dedicated role of chief strategy officer to drive corporate development and the company’s overall growth strategy.

  • Regeneron Q4 Earnings & Sales Beat on Strong Dupixent, Eylea
    Zackslast month

    Regeneron Q4 Earnings & Sales Beat on Strong Dupixent, Eylea

    Regeneron's (REGN) earnings and sales surpass expectations in Q4 on solid Dupixent and Eylea sales.

  • German firm that serves gene therapy biotechs opens Cambridge HQ
    American City Business Journals2 months ago

    German firm that serves gene therapy biotechs opens Cambridge HQ

    Ahead of the opening this week, the German biotech firm signed two major partnerships with Boston-based Orchard Therapeutics and San Francisco-based Denali Therapeutics, and is also in the process of closing another partnership with a U.S. biotech company focused on hemophilia treatments.

  • Celgene (CELG) Q4 Earnings Beat Estimates, Revenues Up Y/Y
    Zacks2 months ago

    Celgene (CELG) Q4 Earnings Beat Estimates, Revenues Up Y/Y

    Celgene (CELG) Q4 earnings beat estimates on robust revenues, driven by strong sales of Otezla and Revlimid.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: bluebird bio and Mirati Therapeutics

    NEW YORK, NY / ACCESSWIRE / January 31, 2019 / U.S. equities regained footing on Wednesday as investors cheered the latest round of corporate earnings and the Federal Reserve kept the interest rates unchanged ...

  • Did bluebird bio, Inc. (NASDAQ:BLUE) Insiders Sell Shares?
    Simply Wall St.2 months ago

    Did bluebird bio, Inc. (NASDAQ:BLUE) Insiders Sell Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that there are more than a few examples Read More...

  • The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio
    Zacks2 months ago

    The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio

    The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio